MET and glioblastoma: MET inhibits the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway when applied to glioblastoma cell lines, primarily by inhibiting PI3K or phosphorylated Akt, as seen in Table 1.